Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal, Karnataka, India.
J Enzyme Inhib Med Chem. 2010 Oct;25(5):730-6. doi: 10.3109/14756361003671045.
Despite being an ancient disease, tuberculosis (TB) remains the leading single-agent infectious disease killer in the world. The emerging serious problem of TB control and clinical management prompted us to synthesize a novel series of heterocyclic substituted diphenyl ether derivatives and determine their activity against the H37Rv strain of Mycobacterium. All ten compounds inhibited the growth of the H37Rv strain of Mycobacterium at concentrations of 1 microg/mL. This activity was found to be comparable to the reference drugs rifampicin and isoniazid at the same concentration. While the antimicrobial activity of other diphenyl ether analogues, such as triclosan, is associated with the inhibition of enoyl-ACP reductase (ENR), the synthesised substituted diphenyl ether derivatives did not affect this enzyme activity in spite of their structural similarity with triclosan. Therefore, these compounds appear to have a novel mechanism of action against M. tuberculosis, and their structural features should be studied further for their potential as new antitubercular drugs.
尽管结核病(TB)是一种古老的疾病,但它仍然是世界上导致单一病原体感染的主要疾病杀手。结核病控制和临床管理方面出现的严重问题促使我们合成了一系列新型杂环取代的二苯醚衍生物,并测定了它们对 H37Rv 株分枝杆菌的活性。所有 10 种化合物在 1μg/ml 的浓度下均能抑制 H37Rv 株分枝杆菌的生长。该活性与相同浓度的参考药物利福平(rifampicin)和异烟肼(isoniazid)相当。虽然其他二苯醚类似物(如三氯生)的抗菌活性与烯酰基辅酶 A 还原酶(ENR)的抑制作用有关,但合成的取代二苯醚衍生物尽管与三氯生结构相似,但并不影响该酶的活性。因此,这些化合物似乎对结核分枝杆菌具有新的作用机制,其结构特征应进一步研究,以评估它们作为新型抗结核药物的潜力。